Vaccines and Clinical Trials · eu
Sanofi launches Phase 3 flu–COVID-19 combination vaccine trial in Europe for adults aged 60 and older
Combining vaccines against two respiratory viruses is one way to simplify vaccination. Sanofi’s new trial will assess the combination’s safety and immune responses, while also making Novavax eligible for a $125 million milestone payment; clinical and regulatory hurdles remain before market launch.
Combining influenza and COVID-19 vaccines could simplify vaccination schedules, but human trials must establish whether the two components can maintain the required immune responses when combined. Novavax announced on October 29 that Sanofi had launched a Phase 3 combination vaccine trial in Europe for adults aged 60 and older, moving the development program into a new stage of evaluation.
The study combines Novavax’s COVID-19 vaccine Nuvaxovid with Sanofi’s marketed high-dose influenza vaccine Efluelda/Fluzone High-Dose to assess safety and immunogenicity—the ability to elicit an immune response after vaccination. Experience with each vaccine individually can provide a foundation for development; the performance of the combined formulation still needs to be established through trial data.
The trial’s launch also marks a concrete financial development. According to Novavax’s 8-K filing submitted on October 29, Sanofi vaccinated the fifth participant in the European Union trial on October 28, triggering a $125 million milestone payment under the companies’ collaboration and licensing agreement. The company expects to receive the payment no later than the first quarter of 2027. S&P Capital IQ’s report on the same day also specified this payment timeline, meaning that meeting the payment conditions and actually receiving the funds remain two separate points in time.
For readers, the key development is that the Phase 3 trial has begun, rather than that new evidence of the vaccine’s protective efficacy is available. The announcement has not disclosed safety or immune response results from this trial, nor has it provided sufficient data to assess actual benefits in preventing infection, hospitalization or severe disease. Even if subsequent immune measures meet expectations, their clinical significance will still need to be assessed based on the complete study results and regulatory requirements.
Progress in the European study also does not directly establish a timeline for a U.S. submission. Novavax cautioned in its announcement that U.S. requirements for this influenza and COVID-19 combination vaccine program may differ from those in other markets, and additional clinical studies may be needed to support a U.S. regulatory submission. A launch date cannot be inferred from this development at this stage.
The collaboration includes other payment conditions that have yet to be met: successful completion of the manufacturing technology transfer would make Novavax eligible for $75 million, which the company currently expects in mid-2027; if Sanofi completes the clinical and regulatory procedures required in the United States and launches the combination vaccine there, a further $225 million payment could be triggered. These arrangements tie future proceeds to manufacturing and launch progress, while the most important scientific question for now remains the combined formulation’s safety and immune responses in older adults.